TrialAnnals of oncology : official journal of the European Society for Medical Oncology2013

A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).

H J M Groen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.